Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤100000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials

HIV Medicine

Volumn 15, Issue 1, 2014, Pages 57-62

  Molina, J M ^a   Clumeck, N ^b   Orkin, C ^c   Rimsky, Lt ^d   Vanveggel, S ^d   Stevens, M ^d  

^a SAINT LOUIS HOSPITAL   (France)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Baseline viral load; Efavirenz; Nonnucleoside reverse transcriptase inhibitor; Rilpivirine; TMC278; Treatment na ve

Indexed keywords

EFAVIRENZ; RILPIVIRINE; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; INFESTATION; INTENTION TO TREAT ANALYSIS; MENTAL DISEASE; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD; VIRUS MUTATION;

BASELINE VIRAL LOAD; EFAVIRENZ; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; TMC278; TREATMENT-NAÏVE;

ADULT; BENZOXAZINES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84888856719     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12071     Document Type: Article

References (14)

1. Janssen Inc. Prescribing information for EDURANT® (rilpivirine) tablets. 2012. Available at www.edurant-info.com/sites/default/files/EDURANT-PI.pdf (accessed 25 July 2013).
2. Janssen-Cilag International NV. EDURANT® (rilpivirine) tablets. Summary of Product Characteristics. 2013. Available at www.medicines.org.uk/EMC/medicine/25490/SPC/Edurant+25+mg/ (accessed 25 July 2013).
3. Molina J-M, Cahn P, Grinsztejn B etal. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-246.
4. Cohen CJ, Andrade-Villanueva J, Clotet B etal. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-237.
5. Cohen C, Molina JM, Cahn P etal. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60: 33-42.
6. Gilead Sciences Ltd. Prescribing information for COMPLERA® (emtricitabine, tenofovir, rilpivirine). 2013. Available at www.gilead.com/pdf/complera_pi.pdf (accessed 25 July 2013).
7. Gilead Sciences Ltd. EVIPLERA® (emtricitabine, tenofovir, rilpivirine). Summary of Product Characteristics. 2013. Available at www.medicines.org.uk/emc/medicine/25518/SPC/Eviplera+200+mg+25+mg+245+mg+film+coated+tablets/ (accessed 25 July 2013).
8. Rimsky L, Vingerhoets J, Van Eygen V etal. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012; 59: 39-46.
9. Molina JM, Clumeck N, Redant K etal. Rilpivirine versus efavirenz in HIV-1 patients with baseline viral load ≤100000 copies/ml: week 48 Phase III analysis. AIDS 2013; 27: 889-897.
10. Vingerhoets J, Rimsky L, Van Eygen V etal. Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response. Antivir Ther 2013; 18: 253-256.
11. Rimsky L, Van Eygen V, Vingerhoets J etal. 96-week resistance analyses of rilpivirine in treatment-naïve, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther 2013 [Epub ahead of print].
12. Arribas JR, Pozniak AL, Gallant JE etal. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78.
13. Wilkin A, Pozniak AL, Morales-Ramirez J etal. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012; 28: 437-446.
14. Cohen C, Molina JM, Cassetti I etal. Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomised trials. AIDS 2013; 27: 939-950.